Perpetua Medical AB (PERP-B) Fair Value & Analysis
Healthcare · Market cap 31.4M SEK (≈ $3.3M) · ISIN SE0022726311
What is Perpetua Medical AB really worth?
Below-average quality, trading 44% below our fair value of kr 4.87.
Strengths
Risks
Fair value as of: Aug 28, 2026
From 15 valuation models · updated 8 days ago
Share price −18.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (kr 3.65). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range kr 0.6912 – kr 238.34 · fair‑value band kr 3.65 – kr 6.09 · the kr 2.75 price screens below the kr 4.87 fair value. Dashed = 300-day average. As of Aug 28, 2026.
Analysis
Perpetua Medical AB (PERP-B) currently trades at kr 2.75, while our model-based Fair Value estimate is kr 4.87, implying the stock looks roughly 43.5% undervalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of kr 13.31 per share, and 11 of the 15 models we run sit above the kr 2.75 price. Bear case: the Asset-Based group reads lowest at kr 1.55, and 4 of the 15 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Perpetua Medical AB generated revenue of 14.6M SEK at a net margin of 16.8%. Revenue grew 23.8% year over year. It earns a return on equity of 5.8%. The balance sheet holds a net cash position of 4.2M SEK. Fundamentals as of Aug 28, 2026
Our scenario range runs from kr 3.65 (bear case) to kr 6.09 (bull case); at kr 2.75, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at 77%, PERP-B screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly kr 0.3873 per share, which is 8.0 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 15 models by family
Widest divergence: Growth Earnings (kr 13.31) versus Asset-Based (kr 1.55). Highest evidence: EPV (74).
Notify me when PERP-B reaches fair value
Put PERP-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 5
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Perpetua Medical AB (publ) provides products and solutions for use of injectable drugs in Sweden. The company provides DrugLog, a solution for reducing medication errors in pharmacy; WasteLog, a device that analysis waste and returns of injectable controlled substances; and PrepLog, a DrugLog based technology platform that integrated prescription software …
Full company description
Perpetua Medical AB (publ) provides products and solutions for use of injectable drugs in Sweden. The company provides DrugLog, a solution for reducing medication errors in pharmacy; WasteLog, a device that analysis waste and returns of injectable controlled substances; and PrepLog, a DrugLog based technology platform that integrated prescription software or medication management system for the test of drug preparations. The company formerly known as Pharmacolog i Uppsala AB (publ) and changed its name to Perpetua Medical AB (publ) in April 2024. Perpetua Medical AB (publ) was incorporated in 2007 and is headquartered in Uppsala, Sweden. Perpetua Medical AB (publ) operates as a subsidiary of Nolsterby Invest AB.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Perpetua Medical AB reported revenue of 14.6M SEK in FY2025 versus 8.8M SEK in FY2021, a compound +13.4%/yr. Reported net income was 2.5M SEK in FY2025.
Watch PERP-B: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 25/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare Perpetua Medical AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Perpetua Medical AB (PERP-B) overvalued or undervalued?
What is the fair value of PERP-B?
What is the quality score of PERP-B?
What is the revenue of Perpetua Medical AB (PERP-B)?
What is the net profit margin of PERP-B?
Watch Perpetua Medical AB in the live analysis
One click puts Perpetua Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.